Artal Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-750,000
| Closed | -$1.13M | – | 139 |
|
|
2023
Q1 | $1.13M | Hold |
750,000
| – | – | 0.07% | 93 |
|
|
2022
Q4 | $749K | Hold |
750,000
| – | – | 0.04% | 109 |
|
|
2022
Q3 | $1.35M | Hold |
750,000
| – | – | 0.06% | 102 |
|
|
2022
Q2 | $2.17M | Hold |
750,000
| – | – | 0.12% | 91 |
|
|
2022
Q1 | $2.07M | Hold |
750,000
| – | – | 0.09% | 112 |
|
|
2021
Q4 | $3.5M | Hold |
750,000
| – | – | 0.09% | 117 |
|
|
2021
Q3 | $6.38M | Hold |
750,000
| – | – | 0.14% | 103 |
|
|
2021
Q2 | $12.3M | Hold |
750,000
| – | – | 0.25% | 80 |
|
|
2021
Q1 | $16.6M | Buy |
750,000
+250,000
| +50% | +$6.82M | 0.29% | 74 |
|
|
2020
Q4 | $15.5M | Hold |
500,000
| – | – | 0.33% | 70 |
|
|
2020
Q3 | $10.2M | Buy |
500,000
+150,000
| +43% | +$2.63M | 0.25% | 78 |
|
|
2020
Q2 | $5.38M | Sell |
350,000
-50,000
| -13% | -$577K | 0.15% | 102 |
|
|
2020
Q1 | $3.1M | Hold |
400,000
| – | – | 0.13% | 90 |
|
|
2019
Q4 | $5.71M | Sell |
400,000
-71,846
| -15% | -$1.11M | 0.22% | 68 |
|
|
2019
Q3 | $7.09M | Sell |
471,846
-18,154
| -4% | -$283K | 0.28% | 61 |
|
|
2019
Q2 | $7.01M | Hold |
490,000
| – | – | 0.28% | 68 |
|
|
2019
Q1 | $8.54M | Buy |
+490,000
| New | +$8.69M | 0.35% | 60 |
|
Artal Group's TCRR Position: Q2 2023 in Review
Artal Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 750,000 shares — an estimated $1.13M sold.
Artal Group first reported a position in TCRR in Q1 2019 and held it in 17 quarters. The position peaked at $16.6M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Artal Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Artal Group sold 750,000 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $1.13M.
- Artal Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 17 quarters.
- Artal Group's TCR2 Therapeutics Inc. Common Stock position peaked at $16.6M in Q1 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.